Skip to main content

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Approximately 8500 patients with type 2 diabetes have been treated with NESINA in 14 randomized, double-blind, controlled clinical trials with approximately 2900 subjects randomized to placebo and approximately 2200 to an active comparator. The mean exposure to NESINA was 40 weeks with more than 2400 subjects treated for more than one year. Among these patients, 63% had a history of hypertension, 51% had a history of dyslipidemia, 25% had a history of myocardial infarction, 8% had a history of unstable angina, and 7% had a history of congestive heart failure. The mean duration of diabetes was 7 years, the mean body mass index (BMI) was 31 kg/m² (51% of patients had a BMI ≥ 30 kg/m²), and the mean age was 57 years (24% of patients ≥ 65 years of age).

Two placebo-controlled monotherapy trials of 12 and 26 weeks of duration were conducted in patients treated with NESINA 12.5 mg daily, NESINA 25 mg daily and placebo. Four placebo-controlled add-on combination therapy trials of 26 weeks duration were also conducted: with metformin, with a sulfonylurea, with a thiazolidinedione, and with insulin.

Five placebo-controlled trials of 16 weeks up through two years in duration were conducted in combination with metformin, in combination with pioglitazone and with pioglitazone added to a background of metformin therapy.

Three active-controlled trials of 52 weeks in duration were conducted in patients treated with pioglitazone and metformin, in combination with metformin and as monotherapy compared to glipizide.

In a pooled analysis of these 14 controlled clinical trials, the overall incidence of adverse events was 66% in patients treated with NESINA 25 mg compared to 62% with placebo and 70% with active comparator. Overall discontinuation of therapy due to adverse events was 4.7% with NESINA 25 mg compared to 4.5% with placebo or 6.2% with active comparator.

Adverse reactions reported in ≥ 4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo are summarized in Table 1.

Table 1: Adverse Reactions Reported in ≥ 4% Patients Treated with NESINA 25 mg and More Frequently Than in Patients Given Placebo in Pooled Studies

  Number of Patients (%)
NESINA 25 mg
Active Comparator
Nasopharyngitis 257 (4.4) 89 (3.0) 113 (5.0)
Headache 247 (4.2) 72 (2.5) 121 (5.4)
Upper respiratory tract infection 247 (4.2) 61 (2.1) 113 (5.0)


In the clinical trial program, pancreatitis was reported in 11 of 5902 (0.2%) patients receiving NESINA 25 mg daily compared to 5 of 5183 ( < 0.1%) patients receiving all comparators.

Hypersensitivity Reactions

In a pooled analysis, the overall incidence of hypersensitivity reactions was 0.6% with NESINA 25 mg compared to 0.8% with all comparators. A single event of serum sickness was reported in a patient treated with NESINA 25 mg.


Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.

In the monotherapy study, the incidence of hypoglycemia was 1.5% in patients treated with NESINa compared to 1.6% with placebo. The use of NESINA as add-on therapy to glyburide or insulin did not increase the incidence of hypoglycemia compared to placebo. In a monotherapy study comparing NESiNa to a sulfonylurea in elderly patients, the incidence of hypoglycemia was 5.4% with NESINA compared to 26% with glipizide (Table 2).

Table 2: Incidence and Rate of Hypoglycemia* in Placebo and Active-Controlled Studies when NESINA was Used as Add-on Therapy to Glyburide, Insulin, Metformin, Pioglitazone, or Compared to Glipizide

Add-on to Glyburide (26 Weeks) NESINA 25 mg + Glyburide Placebo + Glyburide
N=198 N=99
  Overall (%) 19 (9.6) 11 (11.1)
  Severe (%) † 0 1 (1)
Add-on to Insulin (+/- Metformin) (26 Weeks) NESINA 25 mg + Insulin (+/- Metformin) Placebo + Insulin (+/- Metformin)
N=129 N=129
  Overall (%) 35 (27) 31 (24)
  Severe (%) † 1 (0.8) 2 (1.6)
Add-on to Metformin (26 Weeks) NESINA 25 mg + Metformin Placebo + Metformin
N=207 N=104
  Overall (%) 0 3 (2.9)
  Severe (%) † 0 0
Add-on to Pioglitazone (± Metformin or Sulfonylurea) (26 Weeks) NESINA 25 mg + Pioglitazone Placebo + Pioglitazone
N=199 N=97
  Overall (%) 14 (7.0) 5 (5.2)
  Severe (%) † 0 1 (1)
Compared to Glipizide (52 Weeks) NESINA 25 mg Glipizide
N=222 N=219
  Overall (%) 12 (5.4) 57 (26)
  Severe (%) † 0 3 (1.4)
Add on to Metformin (26 Weeks) NESINA 25 mg Metformin 500 mg twice daily
N=112 N=109
  Overall (%) 2 (1.8) 2 (1.8)
  Severe (%) † 0 0
Add on to Metformin Compared to Glipizide (52 Weeks) NESINA 25 mg + Metformin Glipizide + Metformin
N=877 N=869
  Overall (%) 12 (1.4) 207 (23.8)
  Severe (%) † 0 4 (0.5)
*Adverse reactions of hypoglycemia were based on all reports of symptomatic and asymptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-totreat population.
†Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level or loss of consciousness or seizure.

Vital Signs

No clinically meaningful changes in vital signs or in electrocardiograms were observed in patients treated with NESINA.

Laboratory Tests

No clinically meaningful changes in hematology, serum chemistry, or urinalysis were observed in patients treated with NESINA.

Postmarketing Experience

The following adverse reactions have been identified during the postmarketing use of NESINA outside the United States. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and severe cutaneous adverse reactions including Stevens-Johnson syndrome; hepatic enzyme elevations; fulminant hepatic failure; and acute pancreatitis.